The use of real-world evidence (RWE) for medical device regulatory decision-making seems to promise at least a few instances in which the rigors of a clinical trial can be avoided, but a member of the FDA staff said on a conference call that any study aimed at obtaining RWE that could influence the course of therapy might need an investigational device exemption. Read More
